ES2176218T3 - Agente carcinostatico para terapia hormonal que contiene dienogesto como componente activo. - Google Patents

Agente carcinostatico para terapia hormonal que contiene dienogesto como componente activo.

Info

Publication number
ES2176218T3
ES2176218T3 ES94118050T ES94118050T ES2176218T3 ES 2176218 T3 ES2176218 T3 ES 2176218T3 ES 94118050 T ES94118050 T ES 94118050T ES 94118050 T ES94118050 T ES 94118050T ES 2176218 T3 ES2176218 T3 ES 2176218T3
Authority
ES
Spain
Prior art keywords
active component
hormonal therapy
carcinostatic agent
therapy containing
containing dienogest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94118050T
Other languages
English (en)
Inventor
Yasunori Shibutani
Masaomi Obata
Masami Sato
Yukio Katsuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Application granted granted Critical
Publication of ES2176218T3 publication Critical patent/ES2176218T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PRESENTA UN CARCINOSTATICO PARA HORMONOTERAPIA QUE CONTIENE DIENOGEST O SU SOLVATO, QUE SE ESPERA QUE EJERZA EFECTOS TERAPEUTICOS PARA UNA AMPLIA GAMA DE CASOS DE CANCER A MAS BAJAS DOSIS QUE OTROS AGENTES HORMONOTERAPEUTICOS CONVENCIONALES Y QUE ESTA LIBRE DE EFECTOS LATERALES QUE POSEEN LOS PRODUCTOS DE HORMONOTERAPIA CONVENCIONALES A ALTAS DOSIS.
ES94118050T 1993-11-19 1994-11-15 Agente carcinostatico para terapia hormonal que contiene dienogesto como componente activo. Expired - Lifetime ES2176218T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29082393 1993-11-19

Publications (1)

Publication Number Publication Date
ES2176218T3 true ES2176218T3 (es) 2002-12-01

Family

ID=17760949

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94118050T Expired - Lifetime ES2176218T3 (es) 1993-11-19 1994-11-15 Agente carcinostatico para terapia hormonal que contiene dienogesto como componente activo.

Country Status (9)

Country Link
US (1) US5652231A (es)
EP (1) EP0654267B1 (es)
AT (1) ATE215826T1 (es)
AU (1) AU683098B2 (es)
CA (1) CA2136140C (es)
DE (1) DE69430356T2 (es)
DK (1) DK0654267T3 (es)
ES (1) ES2176218T3 (es)
PT (1) PT654267E (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4418102B2 (ja) * 1997-10-17 2010-02-17 持田製薬株式会社 ジエノゲストを有効成分とする子宮筋腫治療剤
AU1690399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
EP1043331A4 (en) * 1997-12-26 2002-05-15 Mochida Pharm Co Ltd DIENOGEST CONTAINING OSTEORESORPTION CYTOKINE INHIBITOR AS ACTIVE INGREDIENT
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE19908762A1 (de) * 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718872A1 (de) * 1976-06-14 1977-12-22 Jenapharm Veb Verfahren zur herstellung von neuen gona-4,9(10)-dienen
JPS6372627A (ja) * 1986-09-17 1988-04-02 Mitsubishi Kasei Corp 子宮内膜症治療薬
JPS643121A (en) * 1987-06-25 1989-01-06 Mitsubishi Kasei Corp Remedy for endometriosis
KR0181264B1 (ko) * 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체

Also Published As

Publication number Publication date
US5652231A (en) 1997-07-29
DK0654267T3 (da) 2002-05-13
EP0654267A1 (en) 1995-05-24
PT654267E (pt) 2002-09-30
CA2136140A1 (en) 1995-05-20
DE69430356T2 (de) 2002-08-14
CA2136140C (en) 2007-10-30
ATE215826T1 (de) 2002-04-15
DE69430356D1 (de) 2002-05-16
AU683098B2 (en) 1997-10-30
AU7888394A (en) 1995-05-25
EP0654267B1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
ZA89233B (en) Topical metronidazole formulations and therapeutic uses thereof
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
EP1370253B8 (en) Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity
KR920019342A (ko) 골질환 치료제
CY1110376T1 (el) Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος
SG52276A1 (en) Aqueous gel retinoid dosage form
BR0315700A (pt) Dispositivo médico implantável que incorpora rapamicina deuterada para a aplicação controlada da mesma
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
ES2137456T3 (es) Agente de tratamiento de las enfermedades hepato-biliares.
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
ES2176218T3 (es) Agente carcinostatico para terapia hormonal que contiene dienogesto como componente activo.
ES2106319T3 (es) Uso de lactoferrina en la fabricacion de un medicamento para el tratamiento del reumatismo.
BR9908885A (pt) Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase
BRPI0416316A (pt) combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
KR930702016A (ko) 골다공증 치료제
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica